Bayer’s pharma lineup churned out growth for yet another quarter, racking up a 5.5% sales hike to €4.1 billion as the blood thinner Xarelto and vision med…

GlaxoSmithKline is not planning to exit the U.K. just because the U.K. is exiting the European Union. As if to emphasize its commitment, the drugmaker today…

Eli Lilly & Co. CEO John Lechleiter is moving on. The outspoken CEO--who presided over a tumultuous period at Lilly, always promising a turnaround--will…

The Philadelphia host committee of the Democratic National Convention has hired a healthcare agency to manage its social media and digital this week--and …

Rebel Depomed investor Starboard Value wants a special meeting as soon as possible--and to get its wish, it’s taking matters into its own hands.

In its second Opdivo tie-up in as many days, Bristol-Myers Squibb has teamed up with Johnson & Johnson to test its drug in yet another variety of lung…

Looking for a bright spot in the gloom of Gilead Sciences’ second-quarter numbers? Look no further than its HIV franchise, where the latest generation of meds…

Earlier this month, Stada proposed a slate of four new directors--but now, as promised, its rebel shareholder is out with an alternative lineup.

Celgene’s best-selling drug Revlimid fell short in a lymphoma trial, putting its hopes for a $1 billion revenue boost in danger.